Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.85 USD | -6.37% | -14.16% | -14.16% |
Financials (USD)
Sales 2024 * | 8.24M | Sales 2025 * | 7.91M | Capitalization | 245M |
---|---|---|---|---|---|
Net income 2024 * | -141M | Net income 2025 * | -172M | EV / Sales 2024 * | 15 x |
Net cash position 2024 * | 122M | Net cash position 2025 * | 171M | EV / Sales 2025 * | 9.3 x |
P/E ratio 2024 * |
-2.16
x | P/E ratio 2025 * |
-2.06
x | Employees | 133 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.75% |
Latest transcript on Monte Rosa Therapeutics, Inc.
1 day | -6.37% | ||
1 week | -14.16% | ||
Current month | -8.83% | ||
1 month | -32.36% | ||
3 months | -0.41% | ||
6 months | +51.09% | ||
Current year | -14.16% |
Managers | Title | Age | Since |
---|---|---|---|
Markus Warmuth
CEO | Chief Executive Officer | 53 | 19-12-31 |
Chief Operating Officer | - | 21-02-28 | |
Filip Janku
CTO | Chief Tech/Sci/R&D Officer | 50 | 21-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Schiff
CHM | Chairman | 58 | 20-08-31 |
Christine Siu
BRD | Director/Board Member | 47 | 20-11-30 |
Chandra Paul Leo
BRD | Director/Board Member | 53 | 20-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.00% | 0 M€ | +9.18% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 4.85 | -6.37% | 150,312 |
24-05-09 | 5.18 | -1.52% | 241,170 |
24-05-08 | 5.26 | -7.39% | 137,485 |
24-05-07 | 5.68 | -1.39% | 189,931 |
24-05-06 | 5.76 | +1.95% | 54,036 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.16% | 245M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- GLUE Stock